By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


Company News
Boehringer Ingelheim Release: New Data Show High Adherence Rates With Pradaxa (Dabigatran Etexilate Mesylate) In NVAF Patients 12/5/2016 9:46:50 AM
Boehringer Ingelheim Release: U.S. FDA Approves Jardiance (Empagliflozin) Tablets To Reduce The Risk Of Cardiovascular Death In Adults With Type 2 Diabetes And Established Cardiovascular Disease 12/5/2016 9:45:18 AM
Boehringer Ingelheim Release: FDA Approves Jardiance To Reduce Cardiovascular Death In Adults With Type 2 Diabetes 12/5/2016 6:30:22 AM
Boehringer Ingelheim to Slash Another 180 Jobs Weeks Before the Holidays 12/2/2016 5:34:12 AM
Boehringer Ingelheim Selects ACD/Labs For International Deployment 11/30/2016 10:26:01 AM
Boehringer Ingelheim And China Southeast University Collaborate To Develop New Treatment Approaches For Hearing Loss 11/28/2016 8:31:35 AM
Boehringer Ingelheim Release: Survey Reveals Most People Don't Know Heart Disease Is The No. 1 Killer Of People With Type 2 Diabetes 11/22/2016 1:43:52 PM
Boehringer Ingelheim Welcomes Central Role Of LABA/LAMA Therapy Within 2017 GOLD Strategy For COPD 11/17/2016 10:21:20 AM
Virtual Biotech Syntimmune Taps Boehringer Ingelheim-Pfizer (PFE) Alum as New CEO and Rakes in Some More Cash to Bring Drugs Into Clinic 11/17/2016 6:10:40 AM
Boehringer Ingelheim Release: Updated Phase III Results Reinforce Safety And Efficacy Of Praxbind (idarucizumab) In Urgent Situations 11/16/2016 12:16:37 PM